How can assessing hemodynamics help to assess volume status?

Authors:
De Backer D; Aissaoui N; Cecconi M; Chew MS; Denault A and 10 more

Journal:
Intensive Care Med

Publication Year: 2022

DOI:
10.1007/s00134-022-06808-9

PMCID:
PMC9363272

PMID:
35945344

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Intensive Care Med

Abbreviation: Intensive Care Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Critical Care

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial.
Meersch M; Weiss R; Strauß C and 11 more (2024) - Transparency Score: 4/6
Clinical practice and effect of carbon dioxide on outcomes in mechanically ventilated acute brain-i…
Robba C; Battaglini D; Abbas A and 10 more (2024) - Transparency Score: 4/6
Equity in patient care in the intensive care unit.
Kotfis K; Olusanya S; Modra L. (2024) - Transparency Score: 2/6
Long-term outcomes with haloperidol versus placebo in acutely admitted adult ICU patients with deli…
Mortensen CB; Andersen-Ranberg NC; Poulsen LM and 23 more (2024) - Transparency Score: 3/6
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute k…
Pickkers P; Angus DC; Bass K and 27 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflicts of interestDDB: Edwards Lifesciences, Philips, Baxter Nadia Aissaoui No conflict of interest. MC: Edwards Lifesciences, Directed Systems. MSC: Edwards Lifesciences. AD: Edwards Lifesciences, Masimo. LH: No conflict of interest. GH: No conflict of interest. AM: Vygon, Edwards, Philips and Getinge. SM: No conflict of interest. MO: Fresenius Medical, Baxter, Biomerieux. MRP: Edwards LifeSciences, Baxter, Intelomed, Exostat. J-LT: Getinge. PV: Baxter. J-LV: No conflict of interest. XM: Gettinge. Conflicts of interest DDB: Edwards Lifesciences, Philips, Baxter Nadia Aissaoui No conflict of interest. MC: Edwards Lifesciences, Directed Systems. MSC: Edwards Lifesciences. AD: Edwards Lifesciences, Masimo. LH: No conflict of interest. GH: No conflict of interest. AM: Vygon, Edwards, Philips and Getinge. SM: No conflict of interest. MO: Fresenius Medical, Baxter, Biomerieux. MRP: Edwards LifeSciences, Baxter, Intelomed, Exostat. J-LT: Getinge. PV: Baxter. J-LV: No conflict of interest. XM: Gettinge."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025